SCHEMBL5753452

SCHEMBL5753452

CCCCCCSc1nc2ccc(S(=O)(=O)N[C@H](Cc3ccccc3)C(=O)O)cc2s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.51
PPARA Q07869 6/20 0.51
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.49
CYP2C9 P11712 1/20 0.49
KMT2A Q03164 1/20 0.49
PPARD Q03181 3/20 0.47
MMP2 P08253 7/20 0.47
MMP9 P14780 5/20 0.47
ADAMTS4 O75173 1/20 0.47
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 1/20 0.43
ADAMTS5 Q9UNA0 1/20 0.43
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757695 0.99 POLB (0.51) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5754992 0.93 MMP2 (0.49) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5756805 0.92 MAPT (0.46) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5757499 0.92 MMP2 (0.50) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5755128 0.92 PPARA (0.52) PPARGPPARAMEN1CYP2C9KMT2A
SCHEMBL5754622 0.91 LDHA (0.47) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5757446 0.91 LDHA (0.47) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5753807 0.91 PPARA (0.51) PPARGPPARAMEN1CYP2C9KMT2A
SCHEMBL5759192 0.89 PPARA (0.44) PPARGPPARAPOLBMEN1CYP2C9
SCHEMBL5756432 0.89 MEN1 (0.52) PPARGPPARAMEN1CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 PPARG 3001/4885PPARA 2744/4885POLB 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.